Antiretrovirus drugs impair kidneys in HIV-infection


Cite item

Full Text

Abstract

Renal damage in HIV infection may result from direct action of HIV and from other causes including nephrotoxic action of medicines. HIV-infected patients receive a wide spectrum of medicines and can be placed in a risk group of drug-induced damage to the kidneys. Risk of nephrotoxicity should be considered in administration of antiretrovirus drugs in HIV patients. Strategy of preventive measures in relation to pharmacological harm to the kidneys consists in early detection of patients with high risk and correction of modifiable risk factors.

About the authors

Nikolay Dmitrievich Yushchuk

Email: shishkina.75@mail.ru

Galina Vladimirovna Volgina

Nataliya Arkad'evna Tomilina

Madina Maratovna Gadzhikulieva

Email: Madina67@mail.ru

N D Yuschuk

Chair of infectious diseases and epidemiology of Moscow State Medicostomatological University, Moscow

Chair of infectious diseases and epidemiology of Moscow State Medicostomatological University, Moscow

G V Volgina

Chair of Nephrology of the postgraduate faculty of Moscow State Medicostomatological University, Moscow

Chair of Nephrology of the postgraduate faculty of Moscow State Medicostomatological University, Moscow

N A Tomilina

Chair of Nephrology of the postgraduate faculty of Moscow State Medicostomatological University, Moscow

Chair of Nephrology of the postgraduate faculty of Moscow State Medicostomatological University, Moscow

M M Gadzhikulieva

Chair of infectious diseases and epidemiology of Moscow State Medicostomatological University, Moscow

Chair of infectious diseases and epidemiology of Moscow State Medicostomatological University, Moscow

References

  1. Hammer S. M., Eron Jr. J. J., Reiss P. et al. Recommendations of the International AIDS Society-USA Panel, 2008. J. A. M. A. 2008; 300 (5): 555-570.
  2. Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. 2009-2010. М.: Р. Валент; 2010.
  3. Jeffrey S., Kasbekar N. Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin. J. Am. Soc. Nephrol. 2006; 1: 117-129.
  4. Jao J., Wyatt C. Antiretroviral medications: adverse effects on the kidney. Adv. Chron. Kidney Dis. 2010; 17 (1): 72-82.
  5. Harris M. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opin. Drug Saf. 2008; 7: 389-400.
  6. Белякова Н. А., Рахманова А. Г. Вирус иммунодефицита человека-медицина. СПб.: Балтийский образовательный центр; 2010.
  7. Izzedine H., Harris M., Perazella M. et al. The nephrotoxic effects of HAART. Nature Rev. Nephrol. 2009; 5: 563-573.
  8. Dasgupta A., Okhuysen P. С. Pharmacokinetic and other drug interactions in patients with AIDS. Ther. Drug Monit. 2001; 23: 591-605.
  9. Zager R. A. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin. Nephrol. 1997; 17: 3-14.
  10. Ciarimboli G., Individual P. K. Cphosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J. Am. Soc. Nephrol. 2005; 16: 1562- 1570.
  11. Rho M., Perazella M. A. Nephrotoxicity associated with antiretroviral therapy in HIV infected patients. Curr. Drug Saf. 2007; 2: 147-154.
  12. Schetz M., Dasta J., Goldstein S., Golper T. Drug-induced acute renal failure. Curr. Opin. Crit. Care 2005; 11 (6): 555- 565.
  13. Wyatt С. М., Arons R. R., Klotman P. E. et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20 (4): 561-565.
  14. Wyatt C., Klotman P. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf. 2006; 5 (2): 275-287.
  15. Fine D., Perazella M., Lucas G. et al. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68 (7): 963-980.
  16. Roe J., Campbell L. J., Ibrahim F. et al. HIV care and the incidence of acute renal failure. Clin. Infect. Dis. 2008; 47: 242-249.
  17. Reiter W. J., Schon-Pernerstorfer H., Dorfinger K. et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J. Urol. (Baltimore). 1999; 161: 1082-1084.
  18. Gallant J. E., Staszewski S., Pozniak A. et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J. A. M. A. 2004; 292 (2): 191-201.
  19. Jaradaе M., Phillips C., Yum M. N. et al. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am. J. Kidney Dis. 2000; 35: 16.
  20. Sarcletti M., Petter A., Romani N. et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin. Nephrol. 2000; 54: 261-270.
  21. Chan-Tack K. M., Truffa M. M., Struble K. A. et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21 (9): 1215-1218.
  22. Krishnan M., Nair R., Haas M. et al. Acute renal failure in an HIV-positive50-year-old man. Am. J. Kidney Dis. 2000; 36: 1075-1078.
  23. Brewster U. С., Perazella M. A. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am. J. Kidney Dis. 2004; 44: 81-84.
  24. Angel-Moreno-Maroto A., Suarez-Castellano L., Hernandez-Cabrera M. et al. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J. Infect. 2006; 52: 39-40.
  25. Knudtson E., Para M., Boswell H. et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstetr. and Gynecol. 2003; 101: 1094-1097.
  26. Joshi M. K., Liu H. H. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDs 2000; 14: 541-548.
  27. Castro J. G., Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am. J. Med. 2002; 112: 505.
  28. Verhelst D., Monge M., Meynard J. L. et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 2002; 40 (6): 1331-1333.
  29. Lyseng-Williamson K. A., Reynolds N. A., Plosker G. L. Tenofovir disoproxil fumarate: A review of its use in the management of HIV infection. Drugs 2005; 65: 413-432.
  30. Morris A. A., Baudouin S. V., Snow M. H. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reversetranscriptase inhibitors. AIDS 2001; 15: 140-141.
  31. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficieniysyndrome. J. Postgrad. 2006; 52: 296-297.
  32. Seguro A. C. Effects of hypokaliemia and hypomagnesemia on zidovudine (AZT) and didanosine (ddI) nephrotoxicity in rats. Clin.Nephrol. 2003; 59: 267-272.
  33. Kopp J. B., Miller K. D., Mican J. A. el al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 1997; 127: 119-125.
  34. Gagnon R. F., Tecimer S. N., Watters A. K. el al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am. J. Kidney Dis. 2000; 36: 507-515.
  35. Hortin G. L., King C., Miller K. D. et al. Detection of indinavir crystals in urine: dependence on method of analysis. Arch. Pathol. Lab. Med. 2000; 124: 246-250.
  36. Sarcletti M., Fetter A., Romani N. et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin. Nephrol. 2000; 54: 261-270.
  37. Nadler R. B., Rubenstein J. N., Eggener S. E. et al. The etiology of urolithiasis in HIV infected patients (Baltimore). J. Urol. 2003; 169: 475-477.
  38. Koster J. C., Remedi M. S., Qiu H. et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52: 1695-1700.
  39. Brown Т. Т. et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 2005; 165: 1179-1180.
  40. Chow D. C., Souza S. A., Chen R. et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin. Trials 2003; 4: 411-416.
  41. Friis-Moller N., Weber R., Reiss P. et al. Cardiovascular disease risk factors in HIV patients-Association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
  42. Seaberg E. C., Munoz A., Lu M. et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960.
  43. Crane H. M., Van Rompaey S. E., Kitahata M. M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019-1026.
  44. Couzigou C., Daudon M., Meynard J. L. et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin. Infect. Dis. 2007; 45 (8): 105-108.
  45. Valencia M. E., Moreno V. Atazanavir-induced nephrolithiasis. Enferm. Infecc. Microbiol. Clin. 2009; 27 (2): 134-135.
  46. Peraldi M. N., Maslo C., Akposso K. et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999; 14: 1578-1585.
  47. Estrella M. M., Parekh R. S., Abraham A. J. et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. Acquir. Immune Defic. Syndr. 2010; 55 (2): 217-220.
  48. Labarga P., Barreiro P., Martin-Carbonero L. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009; 23 (6): 689-696.
  49. European AIDS Clinical Society (EACS) Guidelines. Version 5. Clinical management and treatment of infected adults in Europe. 2009.
  50. Gupta S. K., Eustace J. A., Winston J. A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the infectious Diseases Society of America. Clin. Infect. Dis. 2005; 40 (11): 1559-1585.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies